Search results for HLA A antibody

Anti-HLA-DR antibody [MEM-267], Abcam, AB26089

Anti-HLA-DR antibody [TAL 1B5], Abcam, AB20181

Anti-HLA-DR antibody [TAL 1B5] (ab20181) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt, ICC/IF, IHC-P, WB in human samples. Anti-HLA-DR antibody [TAL 1B5] (ab20181) has been cited over 51 times in peer reviewed journals and is trusted by the scientific community. Abcams high quality manufacturing and validation processes ensure Anti-HLA-DR antibody [TAL 1B5] (ab20181) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-HLA-DR antibody [TAL 1B5] (ab20181) has 6 independent reviews from customers. Anti-HLA-DR antibody [TAL 1B5] (ab20181) specifically detects HLA-DR (UniProt ID: P01903; Molecular weight: 26kDa) and is sold in 100 ug 1 mg selling sizes. Conjugation-ready, carrier free format available for antibody clone TAL 1B5 - ab17648 . Antibody clone TAL 1B5 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor® 647, Alexa Fluor® 488, Alexa Fluor® 555, FITC ( ab22397 , ab39369 , ab3956 , ab31774 ). HLA-DR is a major histocompatibility complex (MHC) class II receptor involved in presenting antigens to T cells, playing a crucial role in the immune response to tumors. High HLA-DR expression on tumor-infiltrating lymphocytes is associated with better clinical outcomes in certain cancers. This product has switched from a hybridoma to recombinant production method on 23 September 2022. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-HLA E antibody [EPR25300-104], Abcam, AB300553

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-HLA E antibody [EPR29073-517], Abcam, AB324677

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Anti-HLA G antibody [EPR23298-97], Abcam, AB283260

What is this antibody validated in? Anti-HLA G antibody [EPR23298-97] (ab283260) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human samples. What is the molecular weight of HLA G? Anti-HLA G [EPR23298-97] (ab283260) specifically detects a band for HLA G (UniProt: P17693) at a molecular weight of 38kDa. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies. Other related products We have a range of other formats of antibody clone [EPR23298-97] also available for your convenience: ab283260, Carrier free - ab283278 , Alexa Fluor® 488 - ab300056 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

HRP Anti-HLA-DP antibody [SP228], Abcam, AB306519

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-HLA A2 antibody [BB7.2], Abcam, AB79523

PE Anti-HLA B7 antibody [BB7.1], Abcam, AB33331

This antibody can be used to distinguish true HLA B27 positives from false HLA B27 positives (i.e. HLA B7 positive) in the investigation of such diseases as ankylosing spondylitis and anterior uveitis.

PE Anti-HLA-DP antibody [SP228], Abcam, AB306517

This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link ® conjugation technology , Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

PE Anti-HLA-DQA1 antibody [EPR7300], Abcam, AB319409

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies . How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.